{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:03:08Z","timestamp":1778900588580,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T00:00:00Z","timestamp":1208822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the existing data on use of the rifamycin class of antibiotics as therapy for Clostridium difficile\u2013associated diarrhea (CDAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was performed using PubMed (1996\u2013January 2008), abstracts from the International Conference on Antimicrobial Agents and Chemotherapy (September 2007), the Infectious Diseases Society of America (October 2007), Salix Pharmaceuticals Web site (January 2008), ActivBiotics Web site (January 2008). Google Scholar, and searches of selected bibliographies using the terms rifamycin, ansamycins, rifampin, rifabutin, rifampicin, rifaximin, rifalazil, Clostridium difficile, C. difficile, and CDAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>In vivo and in vitro studies investigating the use of rifamycins for CDAD were selected, along with all clinical trials using rifamycins in patients with CDAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Nine studies totaling 890 isolates were identified that investigated the in vitro susceptibility of rifampin (6 studies), rifaximin (3 studies), and rifalazil (2 studies). Rifamycins consistently displayed potent activity against tested strains, although strains with decreased susceptibility have been identified. Six published clinical studies involving 81 patients have investigated the use of rifamycins for the treatment of CDAD. These have generally been small studies, although initial positive clinical results have been reported on the use of rifamycins for recurrent CDAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Preliminary data support the use of rifamycins for treatment of CDAD. With the increased incidence and severity of CDAD, further investigation into this drug class as a treatment regimen for CDAD is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1k675","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T23:19:12Z","timestamp":1208906352000},"page":"827-835","source":"Crossref","is-referenced-by-count":55,"title":["Rifamycin Antibiotics for Treatment of Clostridium difficile\u2013Associated Diarrhea"],"prefix":"10.1177","volume":"42","author":[{"given":"Kevin W","family":"Garey","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Salazar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, St. Luke's Episcopal Hospital, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhara","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Rodrigue","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert L","family":"DuPont","sequence":"additional","affiliation":[{"name":"School of Public Health and Baylor College of Medicine, University of Texas\u2014Houston; Chief of Internal Medicine, St. Luke's Episcopal Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,4,22]]},"reference":[{"key":"bibr1-aph.1K675","first-page":"4","volume":"23","author":"Cloud J","year":"2007","journal-title":"Curr Opin Gastroenterol"},{"key":"bibr2-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70215-2"},{"key":"bibr3-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H332"},{"key":"bibr4-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1086\/520276"},{"key":"bibr5-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.3975-3979.2004"},{"key":"bibr6-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.582"},{"key":"bibr7-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.09.008"},{"key":"bibr8-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00479-06"},{"key":"bibr9-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01623-06"},{"key":"bibr10-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1159\/000007297"},{"key":"bibr11-aph.1K675","first-page":"483","volume":"13","author":"Ripa S","year":"1987","journal-title":"Drugs Exp Clin Res"},{"key":"bibr12-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1007\/BF01570982"},{"key":"bibr13-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2607"},{"key":"bibr14-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/11.5.427"},{"key":"bibr15-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2205-2206.2000"},{"key":"bibr16-aph.1K675","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"bibr17-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.3.2.201"},{"key":"bibr18-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.15.6.603"},{"key":"bibr19-aph.1K675","first-page":"S10","author":"Williams R","year":"2005","journal-title":"Rev Gastroenterol Disord"},{"key":"bibr20-aph.1K675","first-page":"51","volume":"14","author":"Descombe JJ","year":"1994","journal-title":"Int J Clin Pharmacol Res"},{"key":"bibr21-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026648812439"},{"key":"bibr22-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050426"},{"key":"bibr23-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)91741-5"},{"key":"bibr24-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1136\/gut.27.10.1169"},{"key":"bibr25-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.10.1361"},{"key":"bibr26-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2749"},{"key":"bibr27-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1080\/004982598239173"},{"key":"bibr28-aph.1K675","author":"Kokkotou E","journal-title":"Presented at: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr29-aph.1K675","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i5.765"},{"key":"bibr30-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198704000-00009"},{"key":"bibr31-aph.1K675","author":"Garey KW","journal-title":"J Clin Gastroenterol"},{"key":"bibr32-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1086\/511870"},{"key":"bibr33-aph.1K675","first-page":"74","volume":"5","author":"Boero M","year":"1990","journal-title":"vancomycin. Microbiologia Medica"},{"key":"bibr34-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1086\/506354"},{"key":"bibr35-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.281.6249.1180-a"},{"key":"bibr36-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199706000-00013"},{"key":"bibr37-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90531-0"},{"key":"bibr38-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31802dfaf7"},{"key":"bibr39-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91881-X"},{"key":"bibr40-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007300745"},{"key":"bibr41-aph.1K675","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200012020-00012"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1K675","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1K675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:10:30Z","timestamp":1777374630000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1K675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,22]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1345\/aph.1K675"],"URL":"https:\/\/doi.org\/10.1345\/aph.1k675","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,22]]}}}